| abstract |
PDE1 inhibitors are provided, processes for their production, their use as pharmaceuticals, and pharmaceutical compositions comprising them, useful for the treatment of Parkinson's diseases, psychosis, schizophrenia, etc., where PDE1 is defined as phosphodiesterase of family I. Claim 1: A compound of formula (1) characterized in that (i) R¹ is H or C₁₋₄ alkyl (for example, methyl or ethyl); (ii) R² and R³ are independently H or C₁₋₆ alkyl (for example, methyl or ethyl); (iii) R⁴ is H or C₁₋₄ alkyl (for example, methyl or ethyl); (iv) R⁵ is aryl (for example, phenyl) optionally substituted with one or more groups selected from C (= O) -C₁₋₆ alkyl (for example, C (= O) CH₃) and hydroxyalkyl C₁₋₆ (for example , 1-hydroxyethyl); (v) R⁶ and R⁷ are independently H or aryl (for example, phenyl) optionally substituted with one or more groups selected from C₁₋₆ alkyl (for example, methyl or ethyl) and halogen (for example, F or Cl) , for example unsubstituted phenyl or phenyl substituted with one or more halogen (eg, F) or phenyl substituted with one or more C₁₋₆ alkyl and one or more halogen or phenyl substituted with a C₁₋₆ alkyl and a halogen, by example 4-fluorophenyl or 3,4-difluorophenyl or 4-fluoro-3-methylphenyl; and (vi) n is 1, 2, 3, or 4; in free or salt form. |